Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$12.88
+0.02 (+0.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $225.8M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.3B
P/E
24.3x
↑EV/EBITDA
9.1x
↓ROE
6.3%
↑Gross Margin
71.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.9%
FCF CAGR
-51.6%
FCF margin
2.7%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.29B · net income $303.9M · FCF $88.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.29B | $3.29B | $3.90B | $4.86B | $4.35B |
| Net Income | $303.9M | $303.9M | $391.9M | $464.2M | $434.5M |
| EBITDA | $562.2M | $562.2M | $606.7M | $642.9M | $637.5M |
| EPS | 0.54 | 0.54 | 0.68 | 0.80 | 0.75 |
| Gross Margin | 71.4% | 71.4% | 73.2% | 74.3% | 72.1% |
| Operating Margin | 11.4% | 11.4% | 9.9% | 9.2% | 10.2% |
| Net Margin | 9.2% | 9.2% | 10.1% | 9.5% | 10.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | — | — | — |
| Current Ratio | 1.94 | 1.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $88.8M | $88.8M | $225.8M | $661.0M | $784.9M |
| Returns | |||||
| ROE | 6.3% | 6.3% | 8.7% | 9.4% | 9.1% |
| Valuation | |||||
| P/E | 24.30 | 24.30 | 19.31 | 26.74 | 26.51 |
| EV/EBITDA | 9.08 | 9.08 | 8.85 | 16.23 | 15.55 |
| P/B | 1.50 | 1.50 | 1.68 | 2.51 | 2.42 |
| Growth & Yield | |||||
| Revenue Growth | -15.5% | -15.5% | -19.9% | 11.8% | — |
| EPS Growth | -20.6% | -20.6% | -15.0% | 6.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.4%
EPS terminal req.
$1.14
Spread vs growth
-49.0%
5Y implied EPS CAGR
20.7%
EPS terminal req.
$1.38
Spread vs growth
-41.3%
10Y implied EPS CAGR
15.2%
EPS terminal req.
$2.23
Spread vs growth
-35.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.5%
Start / end P/E
19.0x → 23.9x
EPS bridge
0.68 → 0.54
Residual
-5.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.